| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Marianne Anderse. Management of endocrine disease: GH excess: diagnosis and medical therapy. European journal of endocrinology. vol 170. issue 1. 2014-01-27. PMID:24144967. |
although the normalisation of gh and igf1 levels is the main objective in all patients with acromegaly, gh and igf1 levels may be discordant, especially during somatostatin analogue therapy. |
2014-01-27 |
2023-08-12 |
human |
| S Kohler, O Tschopp, L Sze, M Neidert, R-L Bernays, K-S Spanaus, P Wiesli, C Schmi. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values? General and comparative endocrinology. vol 188. 2014-01-17. PMID:23648743. |
monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-ghr) gene on "safe" gh cut-off values? |
2014-01-17 |
2023-08-12 |
Not clear |
| S Kohler, O Tschopp, L Sze, M Neidert, R-L Bernays, K-S Spanaus, P Wiesli, C Schmi. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values? General and comparative endocrinology. vol 188. 2014-01-17. PMID:23648743. |
acromegaly is an illness usually defined by excessively high growth hormone (gh) and insulin like growth factor 1 (igf-1) levels, the latter mainly reflecting gh action on the liver. |
2014-01-17 |
2023-08-12 |
Not clear |
| S Kohler, O Tschopp, L Sze, M Neidert, R-L Bernays, K-S Spanaus, P Wiesli, C Schmi. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values? General and comparative endocrinology. vol 188. 2014-01-17. PMID:23648743. |
the diagnosis and management of acromegaly is relatively straight forward, but long-term follow-up of patients can be difficult, as elevated igf-1 levels can occur in the presence of apparently normalised gh levels and late recurrence of acromegaly may arise despite previous suppression on oral glucose tolerance testing. |
2014-01-17 |
2023-08-12 |
Not clear |
| H Nishizawa, H Fukuoka, G Iguchi, N Inoshita, S Yamada, Y Takahash. AIP mutation identified in a patient with acromegaly caused by pituitary somatotroph adenoma with neuronal choristoma. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 121. issue 5. 2013-12-31. PMID:23674160. |
the clinical characteristics of acromegaly associated with aip mutations are reportedly macroadenomas with tumor extension and invasion, lower decreases in gh and igf-i and less tumor shrinkage with ssa treatment, and sparsely granulated somatotroph cell type, which are comparable with those observed in panch. |
2013-12-31 |
2023-08-12 |
Not clear |
| Dan Niculescu, Mariana Purice, Mihail Coculesc. Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly. Pituitary. vol 16. issue 2. 2013-12-24. PMID:22562529. |
active acromegaly is associated with insulin resistance (ir) and glucose intolerance although both gh and igf-i are elevated. |
2013-12-24 |
2023-08-12 |
human |
| Dan Niculescu, Mariana Purice, Mihail Coculesc. Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly. Pituitary. vol 16. issue 2. 2013-12-24. PMID:22562529. |
our objective was to compare whether gh or igf-i correlates more closely with ir and glucose intolerance in acromegaly. |
2013-12-24 |
2023-08-12 |
human |
| Dan Niculescu, Mariana Purice, Mihail Coculesc. Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly. Pituitary. vol 16. issue 2. 2013-12-24. PMID:22562529. |
in multivariate logistic regression analysis igf-i but not gh was a significant risk factor for glucose intolerance after adjusting for age, sex, weight and acromegaly duration (or = 1.56, p = 0.01). |
2013-12-24 |
2023-08-12 |
human |
| Dan Niculescu, Mariana Purice, Mihail Coculesc. Insulin-like growth factor-I correlates more closely than growth hormone with insulin resistance and glucose intolerance in patients with acromegaly. Pituitary. vol 16. issue 2. 2013-12-24. PMID:22562529. |
in acromegaly igf-i correlates more closely than gh with ir. |
2013-12-24 |
2023-08-12 |
human |
| Aleksandra Jawiarczyk-Przybyłowska, Marek Bolanowsk. The role of orexin A in metabolic disturbances in patients with acromegaly. Endokrynologia Polska. vol 63. issue 6. 2013-12-23. PMID:23339004. |
it has been suggested that a defect of orexin a synthesis could be responsible for disturbances in gh synthesis in patients with acromegaly, and consequently aggravate metabolic disturbances caused by high levels of igf1. |
2013-12-23 |
2023-08-12 |
Not clear |
| Carla Chieffo, David Cook, Qinfang Xiang, Lawrence A Frohma. Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly. The Journal of clinical endocrinology and metabolism. vol 98. issue 10. 2013-12-10. PMID:23969184. |
acromegaly is caused by excessive gh secretion and igf-i overproduction. |
2013-12-10 |
2023-08-12 |
Not clear |
| Christoph Schmid, Marian C Neidert, Oliver Tschopp, Lisa Sze, René L Bernay. Growth hormone and Klotho. The Journal of endocrinology. vol 219. issue 2. 2013-12-03. PMID:24096965. |
acromegaly is characterized by excessively high gh and igf1 levels. |
2013-12-03 |
2023-08-12 |
mouse |
| Christoph Schmid, Marian C Neidert, Oliver Tschopp, Lisa Sze, René L Bernay. Growth hormone and Klotho. The Journal of endocrinology. vol 219. issue 2. 2013-12-03. PMID:24096965. |
determination of sklotho in serum and urine (both presumably reflecting gh action on the kidneys) could be used as a supplementary tool in the diagnosis and follow-up of patients with acromegaly. |
2013-12-03 |
2023-08-12 |
mouse |
| Raquel S Jallad, Marcello D Bronstei. The place of medical treatment of acromegaly: current status and perspectives. Expert opinion on pharmacotherapy. vol 14. issue 8. 2013-11-22. PMID:23600991. |
acromegaly is characterized by elevated growth hormone (gh) and insulin-like growth factor-i (igf-i) levels and by progressive somatic disfigurement and systemic manifestations, which lead to a mortality rate higher than the general population. |
2013-11-22 |
2023-08-12 |
Not clear |
| Tove Lekva, Jens Petter Berg, Robert Lyle, Ansgar Heck, Geir Ringstad, Ole Kristoffer Olstad, Annika Elisabet Michelsen, Olivera Casar-Borota, Jens Bollerslev, Thor Uelan. Epithelial splicing regulator protein 1 and alternative splicing in somatotroph adenomas. Endocrinology. vol 154. issue 9. 2013-11-12. PMID:23825128. |
somatotroph adenomas secrete supraphysiological amounts of gh, causing acromegaly. |
2013-11-12 |
2023-08-12 |
human |
| Juan Francisco Martín-Rodríguez, Ainara Madrazo-Atutxa, Eva Venegas-Moreno, Pedro Benito-López, María Ángeles Gálvez, David A Cano, Francisco J Tinahones, Elena Torres-Vela, Alfonso Soto-Moreno, Alfonso Leal-Cerr. Neurocognitive function in acromegaly after surgical resection of GH-secreting adenoma versus naïve acromegaly. PloS one. vol 8. issue 4. 2013-11-04. PMID:23593161. |
patients with active untreated acromegaly show mild to moderate neurocognitive disorders that are associated to chronic exposure to growth hormone (gh) and insulin-like growth factor (igf-i) hypersecretion. |
2013-11-04 |
2023-08-12 |
Not clear |
| Juan Francisco Martín-Rodríguez, Ainara Madrazo-Atutxa, Eva Venegas-Moreno, Pedro Benito-López, María Ángeles Gálvez, David A Cano, Francisco J Tinahones, Elena Torres-Vela, Alfonso Soto-Moreno, Alfonso Leal-Cerr. Neurocognitive function in acromegaly after surgical resection of GH-secreting adenoma versus naïve acromegaly. PloS one. vol 8. issue 4. 2013-11-04. PMID:23593161. |
regression analysis showed longer duration of untreated acromegaly was associated with more severe neurocognitive complications, regardless of the diagnostic group, whereas gh levels at the time of assessment was related to neurocognitive outcome only in naïve patients. |
2013-11-04 |
2023-08-12 |
Not clear |
| G Lombardi, C Di Somma, L F S Grasso, M C Savanelli, A Colao, R Pivonell. The cardiovascular system in growth hormone excess and growth hormone deficiency. Journal of endocrinological investigation. vol 35. issue 11. 2013-10-28. PMID:23143695. |
in patients with acromegaly, chronic gh and igf-i excess commonly causes a specific cardiomyopathy characterized by a concentric cardiac hypertrophy associated with diastolic dysfunction and, in later stages, with systolic dysfunction ending in heart failure if gh/igf-i excess is not controlled. |
2013-10-28 |
2023-08-12 |
Not clear |
| Kentaro Suda, Naoko Inoshita, Genzo Iguchi, Hidenori Fukuoka, Michiko Takahashi, Hitoshi Nishizawa, Masaaki Yamamoto, Shozo Yamada, Yutaka Takahash. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature. Endocrine journal. vol 60. issue 4. 2013-10-22. PMID:23291436. |
in conclusion, we demonstrated that the addition of cabergoline to octreotide lar is a beneficial option in japanese patients with octreotide-resistant acromegaly, irrespective of serum prl levels and the response of gh levels in a bromocriptine test. |
2013-10-22 |
2023-08-12 |
Not clear |
| Akira Shimatsu, Akira Teramoto, Naomi Hizuka, Kazuo Kitai, Joaquim Ramis, Kazuo Chihar. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism. Endocrine journal. vol 60. issue 5. 2013-10-22. PMID:23337477. |
in conclusion, lanreotide autogel provided early and sustained control of elevated gh and igf-i levels, improved acromegaly symptoms, and was well tolerated in japanese patients with acromegaly or pituitary gigantism. |
2013-10-22 |
2023-08-12 |
Not clear |